Pmh24 Effect of Ziprasidone Initial Dosing on Discontinuation in Schizophrenia

Joyce, AT; Ollendorf, DA; Harrison, DJ; Cheli, A

doi:10.1016/s1098-3015(10)66095-0

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both clinical experience (Weiden, 2002) and clinical trials Normalization of cognitive function on ziprasidone versus olanzapine: Results at 6 months. Source: Simpson et al, 2004. data (Joyce, 2004) suggest that initiating ziprasidone therapy at higher doses (120-160 mg/day) may reduce the incidence of activation symptomatology, and make patients significantly less likely to discontinue treatment within the first 6 months than when therapy is initiated at a dose of 80 mg/day or lower. Interestingly, the attrition rate in controlled clinical trials tends to be higher than in actual clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder: Results of a Double-Blind, Six-WeekStudy, with a Six-Month, Double-Blind Continuation Phase

Simpson

Loebel

Warrington

et al. 2006

Prog. Neurother. Neuropsychopharmacol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder: Results of a Double-Blind, Six-WeekStudy, with a Six-Month, Double-Blind Continuation Phase

Simpson

Loebel

Warrington

et al. 2006

Prog. Neurother. Neuropsychopharmacol.

View full text Add to dashboard Cite

“…26 This may help to explain why analysis of a large database found that patients initiating ziprasidone therapy at higher doses (120-160 mg/day) were significantly less likely (hazard ratio, 0.74) to discontinue treatment within the first 6 months of treatment than when therapy was initiated at a dose s80 mg/ day. 27 Symptomatic relief may also be achieved by transient use, in the first 1-3 weeks, of an intermediate or long-acting benzodiazepine (eg, lorazepam or clonazepam).…”

mentioning

confidence: 99%

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

et al. 2005

View full text Add to dashboard Cite

Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. It has a unique receptor profile that includes high-affinity antagonist activity at dopamine D2 receptors, inverse agonist activity at serotonin (5-HT)2A receptors, agonist activity at 5-HT1A receptors, and a relatively high affinity for the serotonin and norepinephrine transporters. The 5-HT1A affinity, together with the inhibitory effect on monoamine reuptake, may underlie the hypothesized beneficial effects on comorbid affective and cognitive abnormalities in schizophrenia and schizoaffective disorder. The short-term efficacy of ziprasidone for core positive symptoms of schizophrenia appears to be comparable to other conventional and atypical antipsychotics. The short-term efficacy of ziprasidone in acute mania has been established based on two 3-week, double-blind, placebo-controlled trials. Open-label treatment for up to 52 weeks confirms the sustained efficacy and safety of ziprasidone in bipolar disorder. Maintenance studies in schizophrenia and schizoaffective disorder indicate that long-term ziprasidone therapy is effective in preventing relapse, while maintaining cognitive and psychosocial benefits. The safety database suggests that the overall cardiovascular and cerebrovascular risk associated with ziprasidone is lower than with other atypicals, with notably lower risk of drug-related increases in weight, glucose, or lipids. The data also suggest a modestly increased risk of QTc prolongation that is not dose related or linked to torsades de pointes. Switching to ziprasidone from other atypicals appears to improve both clinical symptoms and metabolic parameters, though more studies are needed to fully characterize these benefits. This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania.

show abstract

Pmh24 Effect of Ziprasidone Initial Dosing on Discontinuation in Schizophrenia

Cited by 2 publications

References 0 publications

Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder: Results of a Double-Blind, Six-WeekStudy, with a Six-Month, Double-Blind Continuation Phase

Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder: Results of a Double-Blind, Six-WeekStudy, with a Six-Month, Double-Blind Continuation Phase

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

Contact Info

Product

Resources

About